We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Syntimmune

News List

M&As this week: Alexion Pharmaceutical, OvaScience americanpharmaceuticalreview
November 10, 2018
Following the transaction, Syntimmune will add its clinical-stage drug candidate SYNT001 to Alexion’s portfolio.SYNT001 is a humanised monoclonal antibody (mAb) that is currently being evaluated in Phase Ib/IIa studies.
Alexion snaps up another biotech, paying $1.2B for Syntimmune fiercebiotech
September 28, 2018
Alexion’s rebuilding plan has continued with another bolt-on acquisition, this time a $400 million upfront deal for rare disease specialist Syntimmune.
Alexion to acquire Syntimmune biospectrum
September 27, 2018
The deal gives Alexion clinical-stage anti-FcRn antibody SYNT001 with potential to address a number of rare IgG-mediated diseases